Active Ingredient History
Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. Fumazenil is used for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures. Flumazenil went off patent in 2008 so at present generic formulations of this drug are available. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Drug Overdose (approved 2004)
Alcoholism (Phase 2/Phase 3)
Anesthesia, General (Phase 4)
Anxiety (Phase 1)
Brain Death (Early Phase 1)
Brain Injuries (Phase 1/Phase 2)
Delirium (Phase 4)
Dental Anxiety (Phase 1/Phase 2)
Disorders of Excessive Somnolence (Phase 1/Phase 2)
Esophageal and Gastric Varices (Phase 4)
Fragile X Syndrome (Phase 1)
Growth and Development (Phase 1)
Healthy Volunteers (Phase 1/Phase 2)
Heart Arrest (Early Phase 1)
Hepatic Encephalopathy (Phase 1/Phase 2)
Hypnotics and Sedatives (Early Phase 1)
Idiopathic Hypersomnia (Phase 1/Phase 2)
Liver Cirrhosis (Phase 1/Phase 2)
Myotonia (Phase 1)
Myotonic Dystrophy (Phase 1)
Narcolepsy (Phase 1/Phase 2)
Narcotics (Early Phase 1)
Neoplasm Metastasis (Phase 4)
Obsessive-Compulsive Disorder (Phase 2)
Parkinson Disease (Phase 1/Phase 2)
Substance-Related Disorders (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue